凝血酶激活的纤溶抑制物与反复妊娠丢失关系的研究进展

doi:10.11958/j.issn.0253-9896.2015.03.028

天津医药 ›› 2015, Vol. 43 ›› Issue (3): 327-329.doi: 10.11958/j.issn.0253-9896.2015.03.028

凝血酶激活的纤溶抑制物与反复妊娠丢失关系的研究进展

易小芳，谭超#br# #br#

宜昌，三峡大学第一临床医学院检验科（邮编 443002）

收稿日期:2014-05-09 修回日期:2014-11-03 出版日期:2015-03-15 发布日期:2015-03-15
通讯作者: 谭超 E-mail:yczxyytanchao@sina.com
作者简介: 易小芳（1976），女，主管技师，本科，主要从事生殖免疫研究
基金资助:
湖北省自然科学基金（2014CFB307）

Advances on the relationship between thrombin-activatable fibrinolysis inhibitor (TAFI) and recurrent pregnancy loss

YI Xiaofang, TAN Chao#br# #br#

The First Clinical Medical College, China Three Gorges University, Yichang 443002, China

Received:2014-05-09 Revised:2014-11-03 Published:2015-03-15 Online:2015-03-15
Contact: TAN Chao E-mail:yczxyytanchao@sina.com

易小芳，谭超. 凝血酶激活的纤溶抑制物与反复妊娠丢失关系的研究进展[J]. 天津医药, 2015, 43(3): 327-329.

YI Xiaofang, TAN Chao. Advances on the relationship between thrombin-activatable fibrinolysis inhibitor (TAFI) and recurrent pregnancy loss[J]. Tianjin Med J, 2015, 43(3): 327-329.

摘要/Abstract

摘要： 反复妊娠丢失（recurrent pregnancy loss， RPL）是常见于妊娠期的一种并发症，影响着 2%的育龄妇女。最新研究发现高水平凝血酶激活的纤溶抑制物（thrombin-activatable fibrinolysis inhibitor， TAFI）可降低早期 RPL 发生的风险。TAFI 是一种羧肽酶原，激活成活化型 TAFI （TAFIa）后，能够使纤溶酶失去与纤维蛋白的作用位点而发挥纤溶抑制及调节血栓形成的作用。而纤溶系统的损坏是妊娠期妇女发生 RPL 的危险因素之一，关于 TAFI 与 RPL 的研究目前已经成为国内外医学界的研究热点之一。本文结合有关文献就 TAFI 近年来研究现状及与 RPL 的关系进行综述，旨在为临床治疗和预防 RPL 寻找新的方法和线索。

关键词: 凝血酶；纤溶酶原灭活剂；流产, 习惯性；综述；凝血酶激活的纤溶抑制物

Abstract: Recurrent pregnancy loss (RPL) is a common complication of pregnancy, which affects 2% fertile women. A recent research has found that high level of thrombin-activatable fibrinolysis inhibitor (TAFI) can reduce the occurrence risk of early RPL. TAFI is one kind of carboxypeptidase, which can be activated as TAFIa. TAFIa can make the fibrinolysin lose its working site, which can interact with the fibrin to play a role in the regulation of fibrinolysis and the inhibition of throm⁃ bus formation. The damage of fibrinolytic system is one of the risk factors for the occurrence of RPL in pregnant women, which has become one of the hotspots in the medical profession. In this paper, recent literature on TAFI and its relationship with recurrent pregnancy loss has been reviewed, hoping for new ways and clues in clinical treatment and prevention of RPL.

Key words: thrombin, plasminogen inactivators, abortion, habitual, review, thrombin-activatable fibrinolysis inhibitor

参考文献

1. Marx PF, Brondijk THC, Plug T, et al. Crystal structures of TAFI elucidate the inactivation mechanism of activated TAFI: a novel mechanism for enzyme autoregulation[J]. Blood, 2008, 112: 2803–2809. 2. Vercauteren E, Emmerechts J, Peeters M, et al. Evaluation of the profibrinolytic properties of an anti-TAFI monoclonal antibody in a mouse thromboembolism model[J]. Blood, 2011, 117: 4615–4622. 3. Mishra N, Vercauteren E, Develter J, et al. Identification and characterisation of monoclonal antibodies that impair the activation of human thrombin activatable fibrinolysis inhibitor through different mechanisms[J]. J. Thromb Haemost, 2011, 106(1):90-101. 4. Marx PF, Plug T, Havik SR, et al. The activation peptide of thrombin-activatable fibrinolysis inhibitor: a role in activity and stability of the enzyme? J. Thromb Haemost, 2009, 7(3):445-452. 5. Hillmayer K, Vancraenenbroeck R, Maeyer DM, et al. Discovery of novel mechanisms and molecular targets for the inhibition of activated thrombin activatable fibrinolysis inhibitor[J]. J.Thromb Haemost, 2008, 6(11): 1892–1899. 6. Buelens K, Hassanzadeh G, Muyldermans S, et al. Generation and characterization of inhibitory nanobodies towards thrombin activatable fibrinolysis inhibitor[J]. J.Thromb Haemost, 2010,8(6): 1302–1312. 7. Mosnier LO, Buijtenhuijs P, Marx PF, et al. Identification of thrombin activatable fibrinolysis inhibitor (TAFI) in human platelets[J]. Blood, 2003, 101(12): 4844–4846. 8. Gils A, Alessi MC, Brouwers E, et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler Thromb Vasc Biol, 2003, 23(6): 1122–1127. 9. Boffa MB, Maret D, Hamill JD, et al. Effect of single nucleotide polymorphisms on expression of the gene encoding thrombin-activatable fibrinolysis inhibitor: a functional analysis[J]. Blood,2008,111(1): 183–189. 10. Watanabe T, Minakami H, Sakata Y, et al. Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy [J]. Gynecol Obstet Invest , 2004 , 58( 1 ): 19-21. 11. Declerk PJ. Thrombin activatable fibrinolysis inhibitor[J]. Hamostaseologie, 2011, 31(3):165–173. 12.王丽丽,徐成伟. 凝血酶激活的纤溶抑制物TAFI的研究进展[J]. 血栓与止血学,2007,13(1):41-44. 13. Walker JB, Bajzar L. The intrinsic threshold of the fibrinolytic system is modulated by basic carboxypeptidases, but the magnitude of the antifibrinolytic effect of activated thrombin-activable fibrinolysis inhibitor is masked by its instability[J]. J Biol Chem, 2004, 279(27): 27896–27904. 14. Leurs J, Nerme V, Sim Y, et al. Carboxypeptidase U (TAFIa) preventslysis from proceeding into the propagation phase through a threshold-dependent mechanism[J]. J Thromb Haemost, 2004,2(3): 416–423. 15. Heylen E, Willemse J, Hendriks D. An update on the role of carboxypeptidase U (TAFIa) in fibrinolysis[J]. Front Biosci, 2011,1(16): 2427–2450. 16. Folkeringa N, Korteweg FJ, Veeger NJ, et al. Thrombin activatable ?brinolysis inhibitor (TAFI) is not associated with fetal loss, a retrospective study[J]. Thromb Res,2009,123(3): 511–514. 17.Knol HM, Veeger NJ, Middeldorp S, et al. High thrombin-activatable ?brinolysis inhibitor levels may protect against recurrent fetal loss[J]. Thromb Haemost . 2009, 7(5): 903–906. 18. Masini S, Ticconi C, Gravina P, et al. Thrombin-activatable ?brinolysis inhibitor polymorphisms and recurrent pregnancy loss[J]. Fertil Steril, 2009,92(2):694-702. 19. Pruner I, Djordjevic V, Miljic P, et al. +1040C/T polymorphism in coding region of thrombin-activatable fibrinolysis inhibitorgene and the risk of idiopathic recurrent fetal loss[J]. Blood Coagul Fibrinolysis,2010,21(7):679–682. 20. Martinez-Zamora MA, Creus M, Tassies D, et al. Thrombin activatable fibrinolysis inhibitor and clot lysis time in women with recurrent miscarriage associated with the antiphospholipid syndrome[J].Fertil Steril, 2010,94(6):2437–2440. 21. Legnani C, Bovara M, Valdre L, et al. Risk of early recurrent fetal loss and levels of thrombin-activatable ?brinolysis inhibitor[J]. Thromb Res,2011,130(2):237-241. 22. Guo YH, Hernandez I, Isermann B, et al. Caveolin-1-dependent apoptosis induced by ?brin degradation products[J].Blood, 2009,113(18):4431–4439. 23. Kwak-Kim J, Yang KM, Gilman-Sachs A. Recurrent pregnancy loss: A disease of in?ammation and coagulation. J Obstet Gynaecol Res 2009;35(4):609–622. 24. Marx, Pauline F, Chantal J, et al. Recent developments in thrombin-activatable fibrinolysis inhibitor research[J]. Mini Reviews in Medicinal Chemistry,2009, 9(10):1165-1173.

凝血酶激活的纤溶抑制物与反复妊娠丢失关系的研究进展

Advances on the relationship between thrombin-activatable fibrinolysis inhibitor (TAFI) and recurrent pregnancy loss

引用本文

PDF (PC)

可视化

摘要/Abstract

使用本文

参考文献

相关文章 0

编辑推荐

Metrics

本文评价